Quality of life level in patients with diffuse large B-cell lymphoma from high-risk group treated with R-DA-EPOCH regimen
Filonenko K.S., Kriachok I.A., Stepanishyna Y.A., Martynchyk A.V., Titorenko I.B.
Summary. Chemotherapy (CT) intensification can influence on quality of life (QOL) level. QOL was assessed in prospective cohort multicenter study in patients with diffuse large B-cell lymphoma from high-risk group treated with СНОР-like regimens (І group), R-CHOP (ІІ group), and R-DA-EPOCH (ІІІ group). We have compared the QOL levels before and after CT with visual scale of EQ-5D-3L questionnaire. Treatment efficacy was comparable in all groups. Anemia was observed more frequently in І group, neutropenia grade III–IV, neuropathy and transaminase elevation — in III group. QOL was assessed in 40 patients (3 — in І group, 22 — in II group and 15 — in III group). QOL before the treatment in І group was 40%, in ІІ group — 60%, in ІІІ group — 70% (p=0,06). QOL after the end of the therapy was 60; 67.5 and 78%, respectively (p=0,32). Thus, we did not observed statistically significant difference between the groups. QOL changes were statistically significant in all groups (p=0,02). Therefore, treatment with R-DA-EPOCH regimen in diffuse large B-cell lymphoma patients from high-risk group did not decrease the QOL comparing to other regimens.
Leave a comment